On the 4th, HANALL BIOPHARMA, listed on the securities market, is seeing a strong stock price early in the session. It is believed that the buying surge was due to news that a partner company announced positive clinical data.
As of 9:23 a.m. on this day, HANALL BIOPHARMA is trading at 33,850 won, up 2,350 won (7.46%) from the previous trading day.
HANALL BIOPHARMA announced that its partner company Immunovant disclosed data on the maintenance effect after six months of treatment cessation in a Phase 2 clinical trial of batoclimab (HL161BKN) for the treatment of autoimmune disease Graves' disease on the 3rd (local time).
Graves' disease is an autoimmune disorder caused by an abnormal immune system that excessively activates thyroid function. It triggers various symptoms including weight loss, palpitations, and fatigue. Currently, antithyroid drugs (ATD) are used as standard treatment; however, about 20-30% of patients reportedly do not experience sufficient treatment effects or experience relapses.
According to the clinical results, about 80% (17 people) of patients maintained normal thyroid hormone levels for six months after cessation of batoclimab treatment. Among them, about 50% (8 people) maintained stable hormone levels without antithyroid medications, while 30% (5 people) maintained a stable condition while taking a small amount of antithyroid medications.
Jeong Seung-won, CEO of HANALL BIOPHARMA, said, "This data is very significant as it is the first case demonstrating the disease control potential of HL161 in Graves' disease," and expressed hope that, through future planned clinical results, a new treatment paradigm could be presented, providing innovative treatment options for both patients and medical professionals.